What Dolostan Treats: Main Uses and Benefits

The medication Dolostan (Mefenamic Acid) is commonly used to help with symptomatic relief in acute and episodic clinical contexts. The medication is generally applied across domains where additional symptomatic support against pain, inflammation, and fever is needed, supporting general well-being during symptomatic phases.

Dolostan is considered relevant for easing the overall symptom load associated with recurrent gynecological conditions, notably primary dysmenorrhea (painful cramping symptoms) and menorrhagia (abnormally heavy menstrual bleeding). It is also applicable in managing acute pain and inflammatory states, such as headaches, dental pain, and muscular aches.

This provides support that helps ease the overall symptom burden. The medication is often used when symptoms intensify and short-term symptomatic assistance is needed.

Quick Fact: Support for Acute Symptom Clusters
Dolostan is commonly used to address pain and cramping symptoms that create noticeable physiological strain during menstrual cycles, and is relevant in contexts involving post-procedural discomfort.

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Dolostan?

The official regulatory profile for Dolostan (Mefenamic Acid) defines specific populations who can and cannot use the medicine, based strictly on formal contraindications and restricted-use conditions.

Absolute Contraindications

Dolostan must not be used by patients with a known hypersensitivity to Mefenamic Acid or a history of allergic reactions (e.g., asthma, urticaria) to Aspirin or other NSAIDs. Use is strictly contraindicated in patients with active gastrointestinal ulceration, chronic inflammation of the GI tract, or those with severe renal failure, severe hepatic failure, or severe uncontrolled heart failure. The medicine is also prohibited for treating peri-operative pain in the setting of CABG surgery.

Age and Reproductive Status Restrictions

Population	Regulatory Status
Children under 14 years	Not Recommended for general pain use
Pregnancy (Last Trimester)	Contraindicated
Breastfeeding Mothers	Not Recommended

Conditional Use

Caution is required for the elderly due to an increased risk of serious events. Patients with non-severe impaired renal or liver function, uncontrolled hypertension, or a history of epilepsy should only use the medicine with special consideration.

Dolostan's interaction profile is categorized by regulatory restrictions on co-administration and documented alterations to both drug efficacy and systemic exposure. The medication is formally contraindicated for treating pain following Coronary Artery Bypass Graft (CABG) surgery and must not be co-administered with other systemic non-aspirin NSAIDs, including COX-2 inhibitors, due to the increased risk of serious gastrointestinal events.

Pharmacodynamically, co-administration with Oral Anticoagulants (such as Warfarin) and Selective Serotonin Reuptake Inhibitors (SSRIs) is associated with an officially documented increase in the risk of hemorrhage. The efficacy of Diuretics and most Antihypertensive agents, including ACE inhibitors and ARBs, is also subject to pharmacodynamic antagonism, which results in a regulatory-documented reduction of their effect and an increased risk of renal toxicity. Additionally, Mefenamic Acid may interfere with the anti-platelet effect of low-dose Aspirin.

In terms of pharmacokinetics, the absorption of Mefenamic Acid is significantly increased by Magnesium Hydroxide-containing Antacids. Furthermore, the drug reduces the renal clearance of agents like Lithium and Methotrexate, which can lead to elevated plasma concentrations. The regulatory information highlights that co-ingestion of alcohol elevates the risk of gastrointestinal damage, and patients who are poor CYP2C9 metabolizers are noted as a specific population at risk for abnormally high systemic exposure.

Mechanism of Action

The mechanism of action for Dolostan (Mefenamic Acid) is centered on the precise biochemical modulation of the prostaglandin synthesis pathway, influencing physiological responses regulated by the Prostaglandin pathway.

---

Inhibiting Inflammatory Mediator Production

Dolostan acts primarily as a non-selective competitive inhibitor of the Cyclooxygenase (COX) enzymes ( COX-1 and COX-2). By blocking these enzymes, the molecule suppresses the conversion of arachidonic acid into prostaglandins—the lipid mediators that modulate vasodilation, nociception, and thermoregulation. This molecular intervention directly results in the modulation of PGE2-driven effects on tissue responses.

---

Dual Modulation of Nociception and Thermoregulation

The suppression of prostaglandin synthesis initiates a two-pronged physiological effect. Peripherally, the reduced availability of prostaglandins results in decreased chemical sensitization of peripheral nociceptors (pain-sensing nerves). Centrally, the drug's activity in the hypothalamus allows it to suppress PGE2 signals that modulate the body’s thermal set point. This mechanism modulates the physiological signaling pathways associated with nociception and core temperature regulation.

---

Fenamate-Specific Receptor Interference

Beyond enzymatic inhibition, Mefenamic Acid's chemical class (fenamates) is associated with a secondary mechanism: antagonism of specific prostanoid receptors (e.g., EP1). This action targets a downstream signaling event and influences the cellular responses initiated by existing prostaglandins on target cells, particularly influencing the contractility of smooth muscle tissue.

How to Use Dolostan: Administration Guidelines

Dolostan, which contains Mefenamic Acid, is administered orally and is available in forms such as the 250 mg capsule and oral suspension. Usage instructions dictate precise dosing and scheduling patterns that ensure its restricted, short-term application.

Standard Dosing and Frequency

For adults requiring symptomatic management of acute pain or primary dysmenorrhea, the administration begins with an initial 500 mg dose. This is followed by a maintenance dose of 250 mg taken every six hours (q6hr).

Administration for menstrual conditions should be initiated at the onset of bleeding and associated symptoms. For all approved indications, the medicine is directed to be taken with food or milk to reduce the potential for gastrointestinal irritation.

Time Constraints and Special Guidance

The primary principle of use is the shortest possible duration at the lowest effective dose. Treatment for acute pain must be limited and should not exceed a total duration of seven days. For primary dysmenorrhea, use is typically restricted to two to three days per menstrual cycle.

Instructions for a missed dose stipulate that the dose should be skipped, and the individual should continue with the next scheduled dose; doubling up on doses is not permitted. Pediatric use is generally not recommended for children under 14 years of age for these indications, though specific oral suspension regimens exist in some regions for younger populations.

Dolostan: Recent Clinical Evidence

Dolostan (Mefenamic Acid) is a medicine that has been the subject of clinical research. The available evidence describes how the medicine was evaluated for specific, short-term symptomatic conditions. This summary outlines the scope of the research and identifies areas where data is still emerging or insufficient, without providing any clinical guidance.

---

Evidence for Primary Dysmenorrhea (Menstrual Pain)

The evaluation of Dolostan for painful menstrual cramping is widely explored in research, primarily involving short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating symptoms, primarily among female adolescents and young adults. Researchers monitored patient-reported outcomes like pain intensity and tracked the use of concurrent analgesic medication. Studies reported data patterns related to changes in the recorded degree of pain over one to three consecutive cycles. The volume of evidence is substantial, but long-term effects are not fully established, as the research focuses strictly on short-term, episodic symptom patterns.

Evidence for Acute Mild to Moderate Pain

Research has been conducted to examine the medicine in contexts involving conditions associated with acute or disruptive episodes, such as dental discomfort or general aches. This evidence is primarily based on very short-term, randomized controlled trials. Studies monitored outcomes related to physical discomfort, including overall pain intensity scores and tracking the time to onset of symptomatic change. The duration of use explored is strictly limited to acute, short-term changes, with follow-up durations typically restricted to a few days.

Evidence Gaps and Limitations

Research for Dolostan was evaluated in settings relevant to short-term symptom patterns. A key limitation relates to long-term effects, as follow-up durations were limited across the primary studies. There is limited information regarding repeated or chronic use over many months or years. Data for certain groups remain insufficient, including older adults or individuals with multiple existing health conditions. Comparative evidence is also limited regarding studies involving the newest therapeutic options.

Key Studies & References

1. Mefenamic acid and diclofenac in the treatment of menorrhagia and dysmenorrhea in dysfunctional uterine bleeding: a randomized comparative study
2. Non-steroidal anti-inflammatory drugs and cardiovascular risks in the (CHMP Assessment)

Common questions about Dolostan (FAQ)

---

Q: How is Dolostan different from other similar medicines available?

Dolostan belongs to the fenamate class, which is a specific group within the Nonsteroidal Anti-Inflammatory Drug (NSAID) class. Official information describes that fenamates may have a unique secondary action involving prostanoid receptors, in addition to the primary mechanism of blocking COX enzymes. This description is based on regulatory classifications and chemical properties.

---

Q: Is it true that Dolostan can cause long-term side effects?

The official prescribing information advises that the risk of serious adverse events, such as gastrointestinal bleeding or cardiovascular events, may increase with the duration of use. For this reason, official guidelines generally limit the use of Dolostan to short-term application, typically not exceeding seven days for acute conditions.

---

Q: Can I take non-prescription pain relievers while using Dolostan?

Official documents caution against taking Dolostan with other systemic non-aspirin Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including those available over the counter. This is because combining these medicines significantly increases the documented risk of serious gastrointestinal side effects. Consultation with a healthcare provider about all pain relievers being taken is generally recommended.

---

Q: Does Dolostan affect fertility or family planning?

According to the official product information, the use of the medicine may impair female fertility. For this reason, Dolostan is generally not recommended for women who are actively trying to conceive a child.

---

Q: Is Dolostan safe for people with kidney problems?

The medicine is strictly contraindicated (should not be used) in patients diagnosed with severe renal failure. Furthermore, official warnings state that Dolostan should not be administered to patients who have pre-existing kidney disease or significantly impaired kidney function.

---

Q: Does Dolostan interact with herbal supplements or vitamins?

Regulatory labeling requires patients to inform their healthcare professional about all concurrent treatments they are using. This comprehensive advice covers all concurrent treatments, including any herbal products, vitamins, or dietary supplements.

---

Q: What should I do if a common side effect of Dolostan doesn't go away?

The official safety labeling for Dolostan advises that a common adverse effect like diarrhea may become severe enough to require discontinuation of the medicine. For any persistent, worsening, or concerning side effect, patients are generally advised to consult a qualified healthcare professional.

---

Q: Are there any foods I must completely avoid while on Dolostan?

Regulatory documents instruct that patients should take the medicine with food or milk to help reduce the potential for irritation of the stomach or digestive tract. Regulatory information notes that alcohol increases the risk of gastrointestinal damage, and its co-ingestion is typically discouraged. No other specific food restrictions are commonly mandated.

---

Q: How long does the drug substance stay in my system after the last dose?

Pharmacokinetic data, which describes how the body processes the medicine, shows that the elimination half-life of the active substance is approximately two hours. The half-life is the time it takes for the concentration of the medicine in the body to reduce by half.

---

Q: Can Dolostan be used for pain, or is it only for its main purpose?

The medicine is officially indicated for the relief of mild to moderate acute pain in patients 14 years of age and older, in addition to its use for primary dysmenorrhea (menstrual pain). Therefore, the medicine's approved indications cover the relief of mild to moderate acute pain.

---

Q: Is Dolostan typically taken short-term or long-term?

Official guidelines emphasize that Dolostan should be used at the lowest effective dose for the shortest duration possible. Use for acute pain conditions is specifically limited to a maximum of seven days, aligning with its purpose for short-term symptom relief.

---

Q: Does Dolostan start working immediately, or does it take a few days?

Pharmacokinetic data indicates that peak levels of the active substance in the blood are typically attained within one to four hours after oral administration. This measurement of absorption helps estimate when the medicine’s maximum effect begins.

---

Q: Does Dolostan cause weight gain or weight loss?

Official safety information lists fluid retention and edema (swelling) as possible effects associated with the use of Dolostan. This retention of fluid can potentially contribute to unusual weight gain.

---

Q: Is there a generic version of Dolostan available?

The generic name for the active ingredient in Dolostan is Mefenamic Acid. Due to its classification and history, generic formulations containing Mefenamic Acid are widely available.

---

Q: Does Dolostan change how I should be eating or my diet?

Regulatory documents do not mandate any specific changes to a patient's overall diet. However, they state the medicine should be taken with food or milk, as this action helps to reduce the potential for gastrointestinal irritation.

---

Q: What is the risk of dependence or addiction with Dolostan?

Dolostan is a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is not classified as a controlled substance by regulatory bodies. Official information does not note any risk of dependence or addiction associated with its use.

---

Q: Is Dolostan considered an opioid or a controlled substance?

According to its classification, Dolostan is a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is not related to narcotic pain relievers. It is officially classified as neither an opioid nor a controlled substance.

---

Q: Do I need any special blood tests or monitoring while taking Dolostan?

Official labeling advises that blood pressure should be monitored closely during the initiation of treatment. Furthermore, for patients concurrently taking specific drugs, such as oral anticoagulants, frequent monitoring of blood tests like prothrombin time is necessary.

---

Q: Is it normal to feel a bit tired or dizzy when first starting Dolostan?

Official safety documents, listing adverse reactions, include both dizziness and drowsiness as possible effects under the Nervous System Disorders section. This means feeling a bit tired or dizzy is a known possibility while taking the medicine.

---

Q: What is the purpose of the initial clinical trials for Dolostan?

The primary purpose of the initial clinical trials was to generate the required safety and efficacy data. This information was necessary for regulatory agencies (like the FDA or EMA) to grant marketing authorization for the medicine's approved indications.

---

Q: What is the difference between the brand name and the generic name of Dolostan?

The generic name refers to the chemical active ingredient, Mefenamic Acid, while the brand name (Dolostan) is the manufacturer’s specific copyrighted name for the product. Both names describe a product that contains the same active ingredient, strength, and function.

---

Q: Does taking Dolostan affect my ability to drive or operate machinery?

Official labeling cautions that the medicine may cause adverse effects like dizziness, drowsiness, or visual disturbances. Regulatory information indicates that operating heavy machinery or driving should be avoided if these symptoms occur.

---

Q: Is Dolostan known to cause problems with sleep or insomnia?

Official safety documents list insomnia (difficulty sleeping) as a possible adverse effect reported in connection with the medicine.

---

Q: Is it possible to be allergic to an ingredient in Dolostan?

Official regulatory documents state that the medicine is strictly contraindicated (should not be used) for patients who have a known hypersensitivity or allergy to the active substance or any of the other inactive ingredients (excipients) in the product formulation.

---

Q: How is Dolostan metabolized by the body?

The active substance is predominantly metabolized (processed) in the body by the liver. Specifically, this process occurs through the cytochrome P450 CYP 2C9 enzyme pathway, as described in the official pharmacokinetic data.

Storage Requirements

Dolostan (Mefenamic Acid) must be stored at Controlled Room Temperature, which is officially maintained between 20 C and 25 C (68 F and 77 F), with permitted fluctuations up to 30 C.

The medication must be protected from moisture and excessive heat and should be kept from freezing. Store the product in the container it came in, ensuring it is tightly closed to maintain product integrity.

Child-Safety and Disposal

As a mandatory safeguard, Dolostan must be kept out of the reach and sight of children at all times.

For disposal of unused or expired medicine, the official recommendation is to utilize a federal or local drug take-back program. Dolostan is not on the list of medicines that should be flushed. If a take-back option is unavailable, the product should be mixed with an undesirable substance, sealed in a container, and discarded in the household trash, with personal information removed from the original packaging.